Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Nuvectis Pharma Inc (NVCT)

Nuvectis Pharma Inc (NVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 97,957
  • Shares Outstanding, K 19,321
  • Annual Sales, $ 0 K
  • Annual Income, $ -22,260 K
  • EBIT $ -20 M
  • EBITDA $ -20 M
  • 60-Month Beta 0.41
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.72

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.28
  • Number of Estimates 2
  • High Estimate -0.25
  • Low Estimate -0.30
  • Prior Year -0.41
  • Growth Rate Est. (year over year) +31.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.68 +4.59%
on 11/21/24
11.80 -58.47%
on 11/12/24
-2.79 (-36.28%)
since 10/21/24
3-Month
4.68 +4.59%
on 11/21/24
11.80 -58.47%
on 11/12/24
-2.25 (-31.47%)
since 08/21/24
52-Week
4.68 +4.59%
on 11/21/24
12.10 -59.50%
on 03/14/24
-3.22 (-39.66%)
since 11/21/23

Most Recent Stories

More News
Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer

NVCT : 4.90 (-3.35%)
Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights

NVCT : 4.90 (-3.35%)
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics

NVCT : 4.90 (-3.35%)
Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

NVCT : 4.90 (-3.35%)
Bump up Your Long Term Portfolio Performance With Low Beta Stocks

In this article, discover how low beta stocks can shimmer in your portfolio!

MSFT : 412.87 (-0.63%)
NERV : 2.21 (+4.25%)
STIX : 0.3000 (-19.14%)
SERA : 6.11 (+1.33%)
TCRX : 3.94 (-4.37%)
NVCT : 4.90 (-3.35%)
Nuvectis Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Highlights

NXP800 Phase 1a Dose-Escalation Study Progressing as Planned, Commencement of Phase 1b Expansion Study Expected in Q1 2023NXP800 IND Cleared by the U.S....

NVCT : 4.90 (-3.35%)
Nuvectis Pharma Announces Closing of Approximately $15.9 Million Private Placement

Fort Lee, NJ, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused...

NVCT : 4.90 (-3.35%)
5 Best Performing Micro-Cap Stocks Through the First Half of 2022

The first half of 2022 is finally in the books and it could not have come sooner. Major U.S. indices

^BTCUSD : 98,051.62 (+0.07%)
^BTCUSDT : 98,190.86 (+0.61%)
FEDU : 11.28 (+2.41%)
NERV : 2.21 (+4.25%)
TRVI : 2.73 (-1.44%)
NVCT : 4.90 (-3.35%)
HUSA : 1.4200 (-2.74%)
Nuvectis Pharma Announces FDA Clearance of IND for NXP800

FORT LEE, NJ,, June 21, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of...

NVCT : 4.90 (-3.35%)
Nuvectis Pharma Announces Positive Data for NXP900 in a Preclinical Model of Group 4 Medulloblastoma, A Type of Brain Cancer That Affects Predominantly Pediatric Patients

FORT LEE, N.J., June 13, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development...

NVCT : 4.90 (-3.35%)

Business Summary

Nuvectis Pharma Inc. is a biopharmaceutical company. It focused on the development of innovative precision medicines for serious conditions of unmet medical need in oncology. Nuvectis Pharma Inc. is based in Fort Lee, NJ.

See More

Key Turning Points

3rd Resistance Point 5.55
2nd Resistance Point 5.33
1st Resistance Point 5.12
Last Price 4.90
1st Support Level 4.68
2nd Support Level 4.47
3rd Support Level 4.25

See More

52-Week High 12.10
Fibonacci 61.8% 9.27
Fibonacci 50% 8.39
Fibonacci 38.2% 7.52
Last Price 4.90
52-Week Low 4.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar